The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $550 from $535 and keeps a Buy rating on the shares after ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...